Subscribe to RSS
Download PDF
DOI: 10.1055/a-0632-9174
Empfehlung der Sektionen 2 und 11 der DGP zur Rebiopsie bei Lungenkarzinomen
Gemeinsame Stellungnahme der Sektion 2 Endoskopie sowie der Sektion 11 pneumologische Onkologie der Deutschen Gesellschaft für Pneumologie (DGP)Rebiopsy for Patients with Lung Cancer Joint Opinion from both the Endoscopic and Thoracic Oncology Sections of the German Society of Pneumology (DGP)Publication History
Publication Date:
02 August 2018 (online)
Zusammenfassung
Rebiopsien bei primären Lungenkarzinomen sowie deren Metastasen werden im klinischen Alltag immer wichtiger, da sich die Therapien weiterentwickeln und häufig gezielte weitere Behandlungsstrategien erst nach immunhistochemischen oder/und molekularen Veränderungen zugelassen sind. Prinzipiell können fast alle Rezidive bzw. progrediente Tumore biopsiert werden, allerdings häufig nur mittels invasiver Maßnahmen. Hier muss der Aufwand und das Risiko des Patienten mit dem zu erwartenden Benefit durch die Rebiopsie in jedem einzelnen Fall überlegt und vorher mit dem Patienten besprochen werden. In der Übersichtsarbeit werden die Indikationen bei Rezidiv und progredienter Erkrankung sowie die Risiken diskutiert und Alternativen zur Rebiopsie aufgezeigt. Diese Arbeit stellt die Empfehlungen der Sektionen 2 (Endoskopie) und 11 (pneumologische Onkologie) der Deutschen Gesellschaft für Pneumologie (DGP) dar.
Abstract
Performing rebiopsies for primary lung cancer and/or their metastases is becoming more and more prominent in daily practice, as the therapeutical spectrum increases and some newer strategies are dependent on immunohistochemical and/or molecular factors. In general, nearly all recurrent lesions or metastases can be reached. However, frequently invasive procedures are necessary with the need to carefully weigh risks and benefits of rebiopsies for the patient in each case. In this review indications for recurrent and progressive disease as well as risks are discussed and alternatives to rebiopsies are shown. This work is the joint opinion from both the endoscopic and thoracic oncology sections of the German Society of Pneumology (DGP).
-
Literatur
- 1 Reinmuth N, Groschel A, Schumann C. et al. [Updated Recommendation for Treatment of Metastatic Non-Small Cell Lung Cancer]. Pneumologie 2018; 72: 138-154
- 2 Brueckl WM. Treatment choice in EGFR-mutant non-small-cell lung cancer. Lancet Oncol 2017; 18: 1425-1426
- 3 Mahmood S, Vu K, Tai P. et al. Radiation-induced second malignancies. Anticancer Res 2015; 35: 2431-2434
- 4 Rosell R, Karachaliou N. Large-scale screening for somatic mutations in lung cancer. Lancet 2016; 387: 1354-1356
- 5 Reck M, Rabe KF. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2017; 377: 849-861
- 6 Brueckl W, Tufman A, Huber RM. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs. Expert Rev Anticancer Ther 2017; 17: 143-155
- 7 Oxnard GR, Paweletz CP, Kuang Y. et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014; 20: 1698-1705
- 8 Yu HA, Arcila ME, Rekhtman N. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19: 2240-2247
- 9 Mok TS, Wu YL, Ahn MJ. et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med 2017; 376: 629-640
- 10 Doebele RC, Pilling AB, Aisner DL. et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012; 18: 1472-1482
- 11 Heigener D, Reck M. Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer. Expert Rev Anticancer Ther 2015; 15: 69-83
- 12 Reck M, Rodriguez-Abreu D, Robinson AG. et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016; 375: 1823-1833
- 13 Erber R, Stohr R, Herlein S. et al. Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer(R) Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer. Anticancer Res 2017; 37: 6771-6778
- 14 Jin F, Mu D, Chu D. et al. Severe complications of bronchoscopy. Respiration 2008; 76: 429-433
- 15 Facciolongo N, Patelli M, Gasparini S. et al. Incidence of complications in bronchoscopy. Multicentre prospective study of 20,986 bronchoscopies. Monaldi Arch Chest Dis 2009; 71: 8-14
- 16 Jekunen AP. Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments. J Oncol 2015; 2015
- 17 Warth A, Macher-Goeppinger S, Muley T. et al. Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy. Eur Respir J 2012; 39: 1437-1442
- 18 Brueckl WM, Wirtz RM, Bertsch T. et al. [Liquid Biopsy: Detection of Molecular Markers for Treatment Decisions in Lung Cancer]. Pneumologie 2017; 71: 151-163
- 19 Oxnard GR, Thress KS, Alden RS. et al. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2016; 34: 3375-3382
- 20 Schumann C, Hetzel J, Babiak AJ. et al. Cryoprobe biopsy increases the diagnostic yield in endobronchial tumor lesions. J Thorac Cardiovasc Surg 2010; 140: 417-421